THE ROLE OF THE PROPROTEIN CONVERTASE SUBTILISIN / KEXIN TYPE 9 (PCSK9) IN THE PATHOPHYSIOLOGY OF ATHEROSCLEROSIS
Increased serum low-density lipoprotein (LDL) concentrations are clearly the most important risk factors for cardiovascular diseases. Currently, statins are the most widely used drugs for treating patients with hypercholesterolemia, however, in some patients, the residual cardiovascular risk remains...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
The Publishing House Medicine and Enlightenment
2019-12-01
|
| Series: | Medicina v Kuzbasse |
| Subjects: | |
| Online Access: | http://mednauki.ru/index.php/MK/article/view/359 |
| _version_ | 1818205862413467648 |
|---|---|
| author | Алексей Михайлович Чаулин Артем Геннадьевич Александров Ольга Сергеевна Александрова Дмитрий Викторович Дупляков |
| author_facet | Алексей Михайлович Чаулин Артем Геннадьевич Александров Ольга Сергеевна Александрова Дмитрий Викторович Дупляков |
| author_sort | Алексей Михайлович Чаулин |
| collection | DOAJ |
| description | Increased serum low-density lipoprotein (LDL) concentrations are clearly the most important risk factors for cardiovascular diseases. Currently, statins are the most widely used drugs for treating patients with hypercholesterolemia, however, in some patients, the residual cardiovascular risk remains high even after the statin therapy is given with the maximum tolerated dose. A relatively recently discovered protein molecule, the proprotein convertase subtilisin / kexin type 9 (PCSK9), has become a new therapeutic target for lowering serum LDL levels. PCSK9 increases the degradation of low-density lipoprotein receptors (RLDL), which reduces the elimination of LDL particles from the bloodstream, leading to hyperlipidemia and the occurrence of atherosclerosis. In addition to the lipid effects, PCSK9 also has non-lipid functions, among which, the enhancement of inflammatory reactions is of greatest importance for the pathophysiology of atherosclerosis. The review also discusses the possibility of using PCSK9 as a diagnostic marker of cardiovascular diseases. |
| first_indexed | 2024-12-12T04:03:52Z |
| format | Article |
| id | doaj.art-5d8990dd656040a3beddca0aeb5b1bf4 |
| institution | Directory Open Access Journal |
| issn | 1819-0901 2588-0411 |
| language | Russian |
| last_indexed | 2024-12-12T04:03:52Z |
| publishDate | 2019-12-01 |
| publisher | The Publishing House Medicine and Enlightenment |
| record_format | Article |
| series | Medicina v Kuzbasse |
| spelling | doaj.art-5d8990dd656040a3beddca0aeb5b1bf42022-12-22T00:38:49ZrusThe Publishing House Medicine and EnlightenmentMedicina v Kuzbasse1819-09012588-04112019-12-01184515366THE ROLE OF THE PROPROTEIN CONVERTASE SUBTILISIN / KEXIN TYPE 9 (PCSK9) IN THE PATHOPHYSIOLOGY OF ATHEROSCLEROSISАлексей Михайлович Чаулин0Артем Геннадьевич Александров1Ольга Сергеевна Александрова2Дмитрий Викторович Дупляков3ФГБОУ ВО СамГМУ Минздрава России; ГБУЗ «СОККД», г. СамараООО «ИНВИТРО-Самара», г. СамараГБУЗ СО МСЧ № 5, г. СамараФГБОУ ВО СамГМУ Минздрава России; ГБУЗ «СОККД», г. СамараIncreased serum low-density lipoprotein (LDL) concentrations are clearly the most important risk factors for cardiovascular diseases. Currently, statins are the most widely used drugs for treating patients with hypercholesterolemia, however, in some patients, the residual cardiovascular risk remains high even after the statin therapy is given with the maximum tolerated dose. A relatively recently discovered protein molecule, the proprotein convertase subtilisin / kexin type 9 (PCSK9), has become a new therapeutic target for lowering serum LDL levels. PCSK9 increases the degradation of low-density lipoprotein receptors (RLDL), which reduces the elimination of LDL particles from the bloodstream, leading to hyperlipidemia and the occurrence of atherosclerosis. In addition to the lipid effects, PCSK9 also has non-lipid functions, among which, the enhancement of inflammatory reactions is of greatest importance for the pathophysiology of atherosclerosis. The review also discusses the possibility of using PCSK9 as a diagnostic marker of cardiovascular diseases.http://mednauki.ru/index.php/MK/article/view/359пропротеин-конвертаза субтилизин/кексин типа 9 (pcsk9)атеросклерозлипопротеины низкой плотности (лпнп)рецепторы липопротеинов низкой плотности (рлпнп)воспаление |
| spellingShingle | Алексей Михайлович Чаулин Артем Геннадьевич Александров Ольга Сергеевна Александрова Дмитрий Викторович Дупляков THE ROLE OF THE PROPROTEIN CONVERTASE SUBTILISIN / KEXIN TYPE 9 (PCSK9) IN THE PATHOPHYSIOLOGY OF ATHEROSCLEROSIS Medicina v Kuzbasse пропротеин-конвертаза субтилизин/кексин типа 9 (pcsk9) атеросклероз липопротеины низкой плотности (лпнп) рецепторы липопротеинов низкой плотности (рлпнп) воспаление |
| title | THE ROLE OF THE PROPROTEIN CONVERTASE SUBTILISIN / KEXIN TYPE 9 (PCSK9) IN THE PATHOPHYSIOLOGY OF ATHEROSCLEROSIS |
| title_full | THE ROLE OF THE PROPROTEIN CONVERTASE SUBTILISIN / KEXIN TYPE 9 (PCSK9) IN THE PATHOPHYSIOLOGY OF ATHEROSCLEROSIS |
| title_fullStr | THE ROLE OF THE PROPROTEIN CONVERTASE SUBTILISIN / KEXIN TYPE 9 (PCSK9) IN THE PATHOPHYSIOLOGY OF ATHEROSCLEROSIS |
| title_full_unstemmed | THE ROLE OF THE PROPROTEIN CONVERTASE SUBTILISIN / KEXIN TYPE 9 (PCSK9) IN THE PATHOPHYSIOLOGY OF ATHEROSCLEROSIS |
| title_short | THE ROLE OF THE PROPROTEIN CONVERTASE SUBTILISIN / KEXIN TYPE 9 (PCSK9) IN THE PATHOPHYSIOLOGY OF ATHEROSCLEROSIS |
| title_sort | role of the proprotein convertase subtilisin kexin type 9 pcsk9 in the pathophysiology of atherosclerosis |
| topic | пропротеин-конвертаза субтилизин/кексин типа 9 (pcsk9) атеросклероз липопротеины низкой плотности (лпнп) рецепторы липопротеинов низкой плотности (рлпнп) воспаление |
| url | http://mednauki.ru/index.php/MK/article/view/359 |
| work_keys_str_mv | AT aleksejmihajloviččaulin theroleoftheproproteinconvertasesubtilisinkexintype9pcsk9inthepathophysiologyofatherosclerosis AT artemgennadʹevičaleksandrov theroleoftheproproteinconvertasesubtilisinkexintype9pcsk9inthepathophysiologyofatherosclerosis AT olʹgasergeevnaaleksandrova theroleoftheproproteinconvertasesubtilisinkexintype9pcsk9inthepathophysiologyofatherosclerosis AT dmitrijviktorovičduplâkov theroleoftheproproteinconvertasesubtilisinkexintype9pcsk9inthepathophysiologyofatherosclerosis AT aleksejmihajloviččaulin roleoftheproproteinconvertasesubtilisinkexintype9pcsk9inthepathophysiologyofatherosclerosis AT artemgennadʹevičaleksandrov roleoftheproproteinconvertasesubtilisinkexintype9pcsk9inthepathophysiologyofatherosclerosis AT olʹgasergeevnaaleksandrova roleoftheproproteinconvertasesubtilisinkexintype9pcsk9inthepathophysiologyofatherosclerosis AT dmitrijviktorovičduplâkov roleoftheproproteinconvertasesubtilisinkexintype9pcsk9inthepathophysiologyofatherosclerosis |